Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
about
JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative NeoplasmsMegakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connectionOvercoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibTherapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesCirculating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic InterestInflammation as a Driver of Clonal Evolution in Myeloproliferative NeoplasmTo Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory TherapiesClinical potential of pacritinib in the treatment of myelofibrosisTargeting the tumor microenvironment: JAK-STAT3 signalingTargeting JAK2 in the therapy of myeloproliferative neoplasmsCritical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosisAdvances in the management of myelofibrosisThe evolving treatment paradigm in myelofibrosisJanus kinase inhibitors: jackpot or potluck?Aconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling.Identification of Novel Inhibitors of the Type I Interferon Induction Pathway Using Cell-Based High-Throughput ScreeningOncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CMLRuxolitinib in the treatment of polycythemia vera: patient selection and special considerationsTargeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemiaNF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerEmerging therapies for systemic lupus erythematosus--focus on targeting interferon-alphaEfficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasmsHeterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patientsc-Src binds to the cancer drug Ruxolitinib with an active conformationA Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint InflammationFunctional Selectivity in Cytokine Signaling Revealed Through a Pathogenic EPO MutationTargeting substrate-site in Jak2 kinase prevents emergence of genetic resistancePotential strategies for increasing drug-discovery productivity.Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinibRuxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.Ruxolitinib: in the treatment of myelofibrosis.Emerging drugs for myelofibrosis.Ruxolitinib: a new treatment option for myelofibrosis.A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsOptimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.Efficacy of ruxolitinib for myelofibrosis.
P2860
Q21285040-4CF24F36-F954-4B12-8200-0FDEDF8CF729Q24607513-76068CCC-3ABF-467C-893B-9CBD684C535DQ26750696-630A87B2-24E7-4A93-B62C-3A762FA34627Q26752940-0C95B29B-B3CC-4FC4-BBC1-402CA96B4653Q26777398-A94D80CB-CADC-479D-B687-849A55EB717EQ26779936-570FC692-97BF-496C-88CA-87179186EECEQ26786973-94E865CE-AFC0-40CE-AD0B-D2FCED343FE6Q26796450-1B7607A3-DDCD-4DE5-8B07-77426ADAE362Q26825658-3A44103C-0725-4D39-B314-E0C2837A43E3Q26860796-A1F7EF76-5ADB-49CD-A5B6-5A900014A983Q26996258-B70ECF61-ACB4-419D-8533-B8D5B135F681Q27008072-BEE45F3B-F500-491E-AE72-465F383B03CCQ27021968-E146B4F1-EEAB-4EAC-B698-B55A21EB725BQ27027230-E704D38E-68F8-4AE2-AF84-2672DDA6DD54Q27323049-1E2F8B2B-D6E2-4FF3-ABD1-AF9C0490FB26Q27469008-C062AB28-2948-470E-8610-05C706E0BA0EQ27852275-A238C543-D61F-4855-840C-05B9917BA4EEQ28078404-E54C1579-6279-4289-BDDE-E29E7382B841Q28112138-19F143D4-CA48-4A20-B36E-9A8B97BA2219Q28259999-4C95A2E1-ED7E-49DF-A7E0-69F29555B5BBQ28265144-32A3984D-1766-486F-AEB6-50B41E38FBFAQ28271752-5856ADDE-EFCF-4586-B4DC-3345149525ADQ28533511-6AAE7778-AC80-44D9-9EA7-38C47E519D6EQ28542851-1742F071-ECAA-4420-BBDA-956EE32F1497Q28552367-AE31D964-9234-432F-A372-F66267B0FEB9Q29147543-8821FF92-131C-4CDD-AB30-E0037D92D847Q30666276-F5DEB333-55DB-4DC9-9E36-30896208D311Q31154360-2BFC9E66-E77B-4CDF-B0D3-A06F8255D2DBQ33391880-F07A471B-03DA-4E71-95AB-8CB0379A3F31Q33397219-C1BFBCC8-5ABC-4D34-AB0A-7925F752593EQ33399980-14CB9A00-E744-4983-A750-688AAD24BB83Q33402522-EA4B2703-29D7-482A-B4BF-7E6D06CD7EEEQ33403735-BF650E28-9B4E-424E-A984-A59BF4AC8576Q33403784-4A982ACC-0A73-4063-ACFB-24FAA76FCBDCQ33404574-9F879E44-333A-4511-9669-D13DB719200AQ33405241-422BFF8A-E12C-4E39-BBBA-A154EA538A95Q33411637-F1895DF2-75D0-431A-A245-96263ED3E4EEQ33411755-2364B34C-B101-4DE1-99B0-FFD9A55F2BCBQ33411763-07C00549-8627-4079-AB87-8A9400761B1AQ33415489-2DBC5721-C822-46E2-93CA-959076A4A9BC
P2860
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Preclinical characterization o ...... f myeloproliferative neoplasms
@ast
Preclinical characterization o ...... f myeloproliferative neoplasms
@en
Preclinical characterization o ...... f myeloproliferative neoplasms
@nl
type
label
Preclinical characterization o ...... f myeloproliferative neoplasms
@ast
Preclinical characterization o ...... f myeloproliferative neoplasms
@en
Preclinical characterization o ...... f myeloproliferative neoplasms
@nl
prefLabel
Preclinical characterization o ...... f myeloproliferative neoplasms
@ast
Preclinical characterization o ...... f myeloproliferative neoplasms
@en
Preclinical characterization o ...... f myeloproliferative neoplasms
@nl
P2093
P2860
P1433
P1476
Preclinical characterization o ...... f myeloproliferative neoplasms
@en
P2093
Alfonso Quintás-Cardama
Eian Caulder
James D Rodgers
Jennifer Kelley
Jordan S Fridman
Kris Vaddi
Mark Rupar
Maryanne Covington
Patrick Haley
P2860
P304
P356
10.1182/BLOOD-2009-04-214957
P407
P577
2010-02-03T00:00:00Z